Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.42 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | MPL | P40238 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 6/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29890371 | 1.00 | PTPN7 (0.47) | PTPN7DUSP3KDM1AUSP28USP25 | |
| SCHEMBL28558021 | 0.82 | KDM1A (0.37) | PTPN7DUSP3KDM1AUSP28USP25 | |
| SCHEMBL4435565 | 0.82 | GRIN2B (0.39) | PTPN7DUSP3KDM1AUSP28USP25 | |
| SCHEMBL29465742 | 0.82 | GRIN2B (0.39) | PTPN7DUSP3KDM1AUSP28USP25 | |
| SCHEMBL56867 | 0.81 | CYP11B2 (0.53) | KDM1ACYP11B1CYP11B2DGAT1 | |
| SCHEMBL29514712 | 0.81 | CYP11B2 (0.53) | KDM1ACYP11B1CYP11B2DGAT1 | |
| SCHEMBL23003727 | 0.80 | KDM1A (0.36) | PTPN7DUSP3KDM1AUSP28USP25 | |
| SCHEMBL6267032 | 0.80 | KDM1A (0.50) | KDM1ACYP11B1CYP11B2RXRAHCAR1 | |
| SCHEMBL30864218 | 0.80 | KDM1A (0.50) | KDM1ACYP11B1CYP11B2RXRAHCAR1 | |
| SCHEMBL3527105 | 0.79 | PTGDR2 (0.42) | PTPN7DUSP3KDM1ARXRAGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 489 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3543319-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | Johnson Matthey Public Limited Company (GB) | 2019-09-25 | — | — | EP | claimed |
| US-20140120626-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2014-05-01 | — | — | US | claimed |
| EP-2707465-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | Johnson Matthey Public Limited Company (GB) | 2014-03-19 | — | — | EP | claimed |
| WO-2012153132-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2012-11-15 | — | — | WO | claimed |
| CN-122079945-A | Coumarin derivative containing substituted phenyl ether structure, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12630534-B2 | 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-4698517-A1 | <SUP2/>? <SUB2/>?4?NOVEL COMPOUNDS AS ?? <NS1:SUB>7</NS1:SUB>?INHIBITORS | Evotec International GmbH (DE) | 2026-02-25 | — | — | EP | disclosed |
| EP-4692089-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AS AAK1 INHIBITOR | Alicorn Pharmaceutical Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| CN-121045488-A | Wave-transparent resin for aircraft equipment cabin and preparation method thereof | 江苏柯鲁威新材料科技有限公司 | 2025-12-02 | — | — | CN | disclosed |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-10-07 | — | — | US | disclosed |
| US-12427153-B2 | 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2025-09-30 | — | — | US | disclosed |
| US-5696133-A | ADMINISTERING COMPOUND WHICH MODULATES ACTIVITY OF PROGESTERONE RECEPTOR | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5693646-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5693647-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
| US-3947460-A | SEDATIVES-HYPNOTIC, TRANQUILIZER | SANDOZ, INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | PTPN7 3329/4885DUSP3 2963/4885KDM1A 4513/4885 |
| US-12427153-B2 | 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases | CCNA1, CCNA2, CCNT2 | PTPN7 1403/4885DUSP3 1879/4885KDM1A 1110/4885 |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | XBP1, DDIT3, HSP90B1 | PTPN7 3059/4885DUSP3 676/4885KDM1A 3328/4885 |
| US-12630534-B2 | 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression | GPR139, OPRL1, GRIN2C | PTPN7 1353/4885DUSP3 2313/4885KDM1A 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.